We continue to be very positive on Cytori Therapeutics (CYTX) and believe the company’s Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years.

Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results.

Today’s price represents a very attractive entry point in our view. We are maintaining our Outperform rating and $8 target.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (NKTR) Nektar Therapeutics Presents Favorable Phase II Trial DataRecently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant...
2. (CTIC) Cell Therapeutics Releases Encouraging Data for PixantroneYesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone...
3. (OSIR) Osiris Therapeutics’ Prochymal Found IneffectiveWe are disappointed with the failure of Osiris Therapeutics’ (OSIR) Prochymal, a drug derived from...
4. (CTIC) Cell Therapeutics Fails to ImpressWe were disappointed to hear that the US Food and Drug Administration (FDA) has granted...
5. (ALTH) Crucial Time for Allos TherapeuticsWe are awaiting the decision of the US Food and Drug Administration’s (FDA) cancer advisory...
6. (CYTX) Cytori Therapeutics – Bull of the DayWe continue to be very positive on Cytori Therapeutics Inc. (CYTX) and believe the company’s...

Search Posts by Tag: Cytori Therapeutics Inc | CYTX | Biotechnology | Healthcare

RSS Feeds by Tag: Cytori Therapeutics Inc | CYTX | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author